Cosentyx data shows treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis.- Novartis

Novartis, announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis , particularly for American College of Rheumatology 50 (ACR50), and Psoriasis Area and Severity Index (PASI) severity endpoints.

�We are pleased that the data show rapid and sustained improvement across two years in the signs and symptoms of psoriatic arthritis with Cosentyx, regardless of whether patients have enthesitis or not,� said Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology. �Psoriatic arthritis is complex with multiple manifestations driving patient symptoms including enthesitis, which is often associated with more severe disease. At Novartis we are striving to reimagine care in immuno-dermatology and across all manifestations of psoriatic disease to support patients and help them achieve improved quality of life.�.

The abstract, being presented at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) in Madrid, shows that ACR 50, PASI 90 and Quality of life response with secukinumab at month 4 in patients with and without enthesitis is sustained up to 2 years.